If you want to understand why mRNA delivery licensing turned into a web of cross-licenses and royalty stacks, the 2021 patent facet is the place to start. The lipid-nanoparticle delivery space that year was not owned by one company - it was distributed across a handful of heavyweight portfolios.
Aggregating the assignees on the 2021 LNP-delivery set puts Alnylam Pharmaceuticals at the front (the siRNA-delivery pioneer), with ModernaTX and Translate Bio close behind and academic owners - the University of Pennsylvania, the Regents of the University of California, the University of Massachusetts - holding foundational positions. A representative anchor is Translate Bio's US11185595B2, but no single grant defines the field.
The CPC clustering shows why the rights overlap so badly. The top classes - C12N 15/113 (antisense/RNAi), A61K 9/0019 (injectable preparations), A61K 31/713 (siRNA), C12N 2310/14 (interfering RNA) - are shared across siRNA and mRNA programs alike. The same delivery chemistry that carries an siRNA also carries an mRNA, so the siRNA-era LNP patents reach into the mRNA-era products.
That cross-modality overlap is the strategic crux. Alnylam's lead position is not an mRNA accident - it is the residue of a decade of siRNA delivery work that the mRNA wave then had to license or design around. When the foundational delivery chemistry predates the application that made it famous, the original owner holds leverage over the newcomer.
For a freedom-to-operate map in this neighborhood, the discipline is to treat delivery and cargo as separate questions and to aggregate by assignee across both siRNA and mRNA filings before concluding anything. A single in-licence rarely clears the lipid estate; the 2021 facet is the evidence of why.